131 related articles for article (PubMed ID: 20940097)
1. Microscopic and spectroscopic evaluation of novel PLGA-chitosan Nanoplexes as an ocular delivery system.
Jain GK; Pathan SA; Akhter S; Jayabalan N; Talegaonkar S; Khar RK; Ahmad FJ
Colloids Surf B Biointerfaces; 2011 Feb; 82(2):397-403. PubMed ID: 20940097
[TBL] [Abstract][Full Text] [Related]
2. Chitosan/PLGA particles for controlled release of α-tocopherol in the GI tract via oral administration.
Murugeshu A; Astete C; Leonardi C; Morgan T; Sabliov CM
Nanomedicine (Lond); 2011 Nov; 6(9):1513-28. PubMed ID: 21707297
[TBL] [Abstract][Full Text] [Related]
3. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles.
Contreras-Ruiz L; de la Fuente M; García-Vázquez C; Sáez V; Seijo B; Alonso MJ; Calonge M; Diebold Y
Cornea; 2010 May; 29(5):550-8. PubMed ID: 20335805
[TBL] [Abstract][Full Text] [Related]
4. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
5. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells.
Tahara K; Sakai T; Yamamoto H; Takeuchi H; Hirashima N; Kawashima Y
Int J Pharm; 2009 Dec; 382(1-2):198-204. PubMed ID: 19646519
[TBL] [Abstract][Full Text] [Related]
6. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Enríquez de Salamanca A; Diebold Y; Calonge M; García-Vazquez C; Callejo S; Vila A; Alonso MJ
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1416-25. PubMed ID: 16565375
[TBL] [Abstract][Full Text] [Related]
7. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs.
Dong Y; Feng SS
Biomaterials; 2005 Oct; 26(30):6068-76. PubMed ID: 15894372
[TBL] [Abstract][Full Text] [Related]
8. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
Win KY; Feng SS
Biomaterials; 2005 May; 26(15):2713-22. PubMed ID: 15585275
[TBL] [Abstract][Full Text] [Related]
9. The intracellular uptake ability of chitosan-coated Poly (D,L-lactide-co-glycolide) nanoparticles.
Kim BS; Kim CS; Lee KM
Arch Pharm Res; 2008 Aug; 31(8):1050-4. PubMed ID: 18787796
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.
Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
J Drug Target; 2011 Jul; 19(6):409-17. PubMed ID: 20678034
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.
Nafee N; Taetz S; Schneider M; Schaefer UF; Lehr CM
Nanomedicine; 2007 Sep; 3(3):173-83. PubMed ID: 17692575
[TBL] [Abstract][Full Text] [Related]
12. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Diebold Y; Jarrín M; Sáez V; Carvalho EL; Orea M; Calonge M; Seijo B; Alonso MJ
Biomaterials; 2007 Mar; 28(8):1553-64. PubMed ID: 17169422
[TBL] [Abstract][Full Text] [Related]
13. The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells.
Taetz S; Nafee N; Beisner J; Piotrowska K; Baldes C; Mürdter TE; Huwer H; Schneider M; Schaefer UF; Klotz U; Lehr CM
Eur J Pharm Biopharm; 2009 Jun; 72(2):358-69. PubMed ID: 18703137
[TBL] [Abstract][Full Text] [Related]
14. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
15. Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity.
Gaumet M; Gurny R; Delie F
Int J Pharm; 2010 May; 390(1):45-52. PubMed ID: 19833180
[TBL] [Abstract][Full Text] [Related]
16. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
17. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands.
Fischer S; Foerg C; Ellenberger S; Merkle HP; Gander B
J Control Release; 2006 Mar; 111(1-2):135-44. PubMed ID: 16377017
[TBL] [Abstract][Full Text] [Related]
18. Flow Focusing: a versatile technology to produce size-controlled and specific-morphology microparticles.
Martín-Banderas L; Flores-Mosquera M; Riesco-Chueca P; Rodríguez-Gil A; Cebolla A; Chávez S; Gañán-Calvo AM
Small; 2005 Jul; 1(7):688-92. PubMed ID: 17193506
[TBL] [Abstract][Full Text] [Related]
19. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
20. Cellular uptake of Poly-(D,L-lactide-co-glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method.
Xiong S; Zhao X; Heng BC; Ng KW; Loo JS
Biotechnol J; 2011 May; 6(5):501-8. PubMed ID: 21259442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
